Schedule At A Glance
Thursday, January 19, 2023 7:00 AM-8:00 AM Complimentary Continental Breakfast 7:00 AM-5:45 PM...
Read MoreJan 13, 2023
Thursday, January 19, 2023 7:00 AM-8:00 AM Complimentary Continental Breakfast 7:00 AM-5:45 PM...
Read MoreJan 13, 2023
Therapy with atezolizumab (atezo) plus bevacizumab (bev) in systemic treatment (tx)-naive patients...
Read MoreJan 13, 2023
Atezolizumab plus bevacizumab (A+B) is the new standard of care for first-line treatment of...
Read MoreJan 13, 2023
In the treatment of hepatocellular carcinoma (HCC), immune checkpoint inhibitor (ICI) based...
Read MoreJan 13, 2023
Hepatocellular carcinoma (HCC) is the most rapidly expanding cause of cancer-related mortality in...
Read MoreDec 21, 2022
Patients with chronic lymphocytic leukemia (CLL) infected with COVID-19 during the most recent...
Read MoreDec 21, 2022
The ACR 2022 PhysQuiz was created by the editorial staff at Physician’s...
Read MoreDec 19, 2022
Measurable/minimal residual disease (MRD) assessment by qPCR was strongly associated with clinical...
Read MoreDec 19, 2022
The triplet combination of azacitidine, venetoclax, and gilteritinib induced high response rates...
Read MoreDec 19, 2022
Patients with relapsed or refractory mantle cell lymphoma (MCL) and a high CAR-hematotox score had...
Read MoreDec 19, 2022
A new, real-world study using more than 2 years of EMRs shows that patients with chronic...
Read MoreDec 19, 2022
A quiz based on the latest lung cancer news and studies from SOHO.
Read MoreDec 16, 2022
The ASN 2022 PhysQuiz was created by the editorial staff at Physician’s...
Read MoreDec 16, 2022
Metabolic tumor volume (MTV) was reported at the 2022 annual meeting of the American Society of...
Read MoreDec 15, 2022
measurable residual disease (MRD)-negative showed an overall survival (OS) benefit if they were...
Read MoreDec 15, 2022
Post-transplant cyclophosphamide/tacrolimus/mycophenolate mofetil outperformed...
Read MoreDec 15, 2022
Odronextamab, an investigational bi-specific antibody targeting CD20 and CD3, showed promising...
Read More